Published on 16 Aug 2023 on Simply Wall St. via Yahoo Finance

Downgrade: Here's How Analysts See RVL Pharmaceuticals plc (NASDAQ:RVLP) Performing In The Near Term

The analysts covering RVL Pharmaceuticals plc (NASDAQ:RVLP) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.

Following the latest downgrade, RVL Pharmaceuticals' four analysts currently expect revenues in 2023 to be US$36m, approximately in line with the last 12 months. Losses are predicted to fall substantially, shrinking 24% to US$0.52 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$49m and losses of US$0.40 per share in 2023. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.

Check out our latest analysis for RVL Pharmaceuticals